OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

CPTAC Releases UCEC, ccRCC Discovery Data and Other Study Datasets

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is releasing the latest proteomic discovery datasets for Uterine Corpus Endometrial Carcinoma (UCEC) and Clear Cell Renal Cell Carcinoma (ccRCC).

CPTAC has previously demonstrated how proteogenomics reveals new insights into cancer...


CPTAC Develops Fit-for-Purpose Immuno-MRM Assay for FANCD2 Protein Modification Involved in DNA Damage

Fanconi anemia (FA) is a rare inherited disorder characterized by progressive bone marrow failure and an increased risk of developing certain types of cancer. The FA pathway consists of a network of 21...


Cancer Has No Borders – NCI Video Release Highlights the International Cancer Proteogenome Consortium

The Office of Cancer Clinical Proteomics Research of the National Cancer Institute (NCI), part of the National Institutes of Health, announces the release of a video titled, “International Cancer Proteogenome Consortium (ICPC)”. Launched during the 2018 Human Proteome Organization World Congress...


The precisionFDA NCI-CPTAC Multi-Omics Challenge is Open for Submissions

The National Cancer Institute in partnership with the Food and Drug Administration is pleased to announce the launch of the precisionFDA NCI-CPTAC Multi-Omics Challenge. The aim of this...


CPTAC and FDA Discuss Upcoming Computational Challenge in the Journal Nature Medicine

Multidimensional multi-omics datasets from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumor Analysis Consortium (CPTAC), and similar initiatives are becoming a powerful approach to...


CPTAC Evaluates SEER Repository Tissues as a Resource for Population-Based Cancer Proteomic Studies

Next-generation mass spectrometry (NGMS) has become a powerful tool for protein identification and quantification from prospectively collected fresh frozen or optimal cutting temperature embedded specimens. However, limitations due to supply, accessibility, and delay of clinical information and...


Get Ready to Join the precisionFDA NCI-CPTAC Multi-Omics Challenge

In biomedical research, sample mislabeling or incorrect annotation has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies where human errors could arise during sample...


CPTAC Optimizes Proteomic Workflow for Cancer Research

In recent years, proteomic technologies have emerged as invaluable tools in cancer research. Next-generation mass spectrometry (NGMS) is being used to study cancer biology, while providing the cancer research community with a growing body of biological knowledge that may lead to more effective...


Agarwal Laboratory Demonstrates a Potential Therapeutic Strategy for Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogenous malignancy that stems from the production of abnormal white blood cells, platelets, or red blood cells in the bone marrow. It is estimated that 19,520 new...


Reminder: NCI Requests Cancer Targets for Monoclonal Antibody Production and Characterization

In an effort to improve rigor and reproducibility, the National Cancer Institute (NCI) Antibody Characterization Program requests cancer-related protein targets for monoclonal antibody production...


Pages